-
Garbutt and colleagues performed a randomized placebo controlled trial designed to evaluate the efficacy of antibiotic therapy in patients with a clinical diagnosis of acute rhinosinusitis at 10 primary care practices in St. Louis.
-
The concern regarding influenza infection is high in cancer patients since the rate of infection is considerably higher and mortality is four times greater than in the general population.
-
Trying to rein in the widespread misuse of antibiotics that is driving the rise of pan-resistant infections, the Centers for Disease Control and Prevention has created an electronic tracking system that will allow hospitals to monitor and benchmark drug use much as they already do for health care associated infections (HAIs).
-
As a key complement to its new antibiotic use tracking system, the Centers for Disease Control and Prevention is partnering with the Institute for Healthcare Improvement (IHI) in a pilot program to prevent overuse and misuse of antibiotics in hospitals.
-
While emerging multidrug resistant gram negative rods are a prime topic of current concern, there is a sobering reminder that longstanding foes have not exactly been vanquished.
-
Getting a flu shot doesn't provide as much protection as was previously reported, according to new analysis of more than 5,000 studies. Now it's time to be honest about the limitations of the vaccine to build trust with health care workers, says an international expert in risk communication.
-
More health care workers than ever are receiving the influenza vaccine. A national survey shows that by mid-November, about 78% of them had been vaccinated a rate that is almost double the rate of about five years ago.
-
Infection preventionists are keeping their heads above water in a brutal economy, though they may be understandably confused about which hat they have on them.
-
Outpatients with a diagnosis of either dentoalveolar or periodontal abscess or a diagnosis of gingival inflammatory infiltrates were randomized to receive either moxifloxacin 400 mg daily or clindamycin 300 mg QID, both for 5 days, in a prospective, randomized, placebo-controlled, double-dummy clinical trial design.
-
This report details the occurrence of an infected, cellulitic lower extremity wound infection in a 70-year-old British woman secondary to an unusual Vibrio species, V. alginolyticus.
